The Lynx Group

Rogerio Lilenbaum, MD


Authored Items

Test for EGFR Mutation in All Patients with NSCLC
Matching Treatment to Molecular Alteration Yields Best Outcomes

May 2016, Vol. 5, No. 4 - National Comprehensive Cancer Network

Tyrosine kinase inhibitors (TKIs) are the mainstay of treatment for patients with EGFR mutation–positive non–small cell lung cancer (NSCLC), according to the most recent guideline on management of NSCLC issued by the National Comprehensive Cancer Network (NCCN). Version 4.2016 of the guideline recommends EGFR testing as part of broader molecular [ Read More ]

Sign me up!